TY - JOUR
T1 - Antiglaucoma medications
T2 - A review of safety and tolerability issues related to their use
AU - Schuman, Joel S.
N1 - Funding Information:
The author receives grant and research support from Alcon Laboratories, Inc., Fort Worth, Texas; Allergan, Inc., Irvine, California; Merck & Co., Inc., West Point, Pennsylvania; and Pharmacia & Upjohn, Kalamazoo, Michigan.
Funding Information:
The author gratefully acknowledges Bianca B. Ruzicka, PhD, (OCC-West, Alameda, California), and Jacqueline Conner-Bailey, PharmD (Bedford, New Hampshire), for their contributions to this manuscript. OCC-West received an unrestricted educational grant from Allergan, Inc. Dr. Conner-Bailey received compensation from OCC-West for assistancei n the preparation of this manuscript.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Background: Much experience has been gained with the use of older classes of antiglaucoma agents-topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha2- adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use. Objective: This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.
AB - Background: Much experience has been gained with the use of older classes of antiglaucoma agents-topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha2- adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use. Objective: This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.
KW - Adverse effects
KW - Beta-adrenergic-receptor antagonists
KW - Carbonic anhydrase inhibitors
KW - Cholinergic agents
KW - Glaucoma
KW - Prostaglandin analogues
UR - http://www.scopus.com/inward/record.url?scp=0034017979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034017979&partnerID=8YFLogxK
U2 - 10.1016/S0149-2918(00)88478-7
DO - 10.1016/S0149-2918(00)88478-7
M3 - Article
C2 - 10743979
AN - SCOPUS:0034017979
SN - 0149-2918
VL - 22
SP - 167
EP - 208
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 2
ER -